Closing the Gap in Long-Term Care
Cardiovascular diseases remain among the leading causes of mortality across Europe. While acute care is highly developed, a persistent gap exists after hospital discharge: long-term prevention, patient adherence, and lifestyle modification.
This is where many healthcare systems struggle. Patients often fall out of structured care pathways, adherence drops over time, and follow-up resources are limited. In Austria, this challenge is particularly visible in secondary prevention, where structured long-term support is not always consistently implemented.
Digital therapeutics (DTx) in vascular diseases are increasingly positioned to address exactly this gap. However, despite growing interest, their integration into routine care remains limited.
Beyond Technology – Real Clinical Impact
Digital therapeutics are not just apps or wellness tools. They are software-based interventions designed to deliver measurable clinical outcomes.
Recent research in cardiovascular contexts highlights several relevant effects:
- Improved patient adherence to therapy and lifestyle interventions
- Increased participation in rehabilitation programs
- Better short-term control of risk factors such as physical inactivity or medication compliance
However, there are important nuances:
- Evidence for long-term outcomes (e.g., mortality or major adverse cardiovascular events) is still limited
- Patient engagement tends to decline over time without strong behavioral design
- Clinical validation varies significantly across solutions
This creates a critical distinction: Digital therapeutics in vascular diseases should therefore be understood as a scalable extension of care, not a replacement for traditional treatment. For healthcare systems under pressure, this distinction is highly relevant.
The European and Austrian Landscape
A Fragmented European Ecosystem
Within the EU, digital therapeutics operate in a complex environment:
- Regulatory pathways are influenced by the Medical Device Regulation (MDR)
- Reimbursement frameworks differ widely between countries
- Evidence expectations are not fully standardized
This leads to a fragmented market where scaling across borders remains difficult.
Austria: High Potential, Structural Constraints
Austria presents a mixed picture:
Strengths:
- Strong clinical infrastructure
- High-quality acute care
- Increasing openness toward digital health solutions
Challenges:
- No clearly defined reimbursement pathway for DTx
- Limited integration into existing clinical workflows
- Uncertainty among stakeholders regarding clinical and economic value
Studies in the Austrian context indicate that while healthcare professionals are generally open to digital innovation, practical implementation barriers persist, especially around usability, interoperability, and evidence requirements. Digital therapeutics adoption in Austria is therefore progressing, but at a slower pace than technological innovation would allow.
A Shifting Data Landscape
With initiatives like the European Health Data Space (EHDS), the environment is evolving:
- Greater access to health data
- New opportunities for real-world evidence generation
- Increased requirements for data governance and compliance
For DTx developers and clinical trial sponsors, this means one thing:
Data strategy is becoming as important as clinical strategy.
What to Consider When Developing or Evaluating DTx
Whether you are a MedTech company, sponsor, or healthcare innovator, several practical factors determine success:
1. Design for long-term engagement
Short-term adherence gains are common. Sustained engagement is not. Invest in behavioral design, personalization, and user experience early.
2. Think beyond traditional endpoints
In vascular diseases, relevant outcomes include:
- Clinical endpoints (e.g., stroke recurrence)
- Behavioral metrics (activity levels, adherence)
- Digital biomarkers (continuous monitoring data)
A hybrid endpoint strategy is often necessary.
3. Integrate into clinical workflows
Standalone solutions face adoption barriers. Align DTx with existing care pathways, physician workflows, and rehabilitation programs.
4. Plan for reimbursement early
In Austria and across the EU, reimbursement is not guaranteed. Build evidence not only for clinical efficacy but also for:
- Cost-effectiveness
- System-level impact
- Resource optimization
5. Use real-world data strategically
Randomized controlled trials (RCTs) remain important, but are often not sufficient. Combine RCTs with real-world evidence to strengthen your value proposition.
From Innovation to Implementation
Digital therapeutics have clear potential in vascular care, particularly in closing the gap between acute treatment and long-term prevention.
The current evidence supports their role in improving adherence and patient engagement. However, their broader impact depends on factors that go beyond technology:
- regulatory clarity
- reimbursement pathways
- integration into healthcare systems
- sustained patient engagement
In Austria, the opportunity is present, but so are the structural challenges. Moving forward requires a coordinated approach between developers, clinicians, regulators, statutory health insurers and healthcare funders.
References
- Yang, L., Wang, Z., Zhao, S. et al. (2025). Effectiveness of digital healthcare to improve clinical outcomes in discharged patients with coronary artery disease. Nature Publishing Group Digit. Med. 8, 473.
https://doi.org/10.1038/s41746-025-01655-6 - Qi, Y., Mohamad, E., Azlan, A. A., Zhang, C., Ma, Y., & Wu, A. (2025). Digital health solutions for cardiovascular disease prevention: Systematic review. Journal of Medical Internet Research, 27, e64981.
https://doi.org/10.2196/64981 - Shao, X., Hu, Y., Jia, H., & Song, J. (2025). Digital Therapeutics in Cardiovascular Healthcare: A Narrative Review. Current cardiology reports, 27(1), 119. https://doi.org/10.1007/s11886-025-02270-3
- Krusche J., Eichenberg C. (2025). E-Health und E-Mental-Health-Anwendungen bei Herz-Kreislauf-Erkrankungen // E-mental healt applications for cardiovascular diseases. Journal für Kardiologie – Austrian Journal of Cardiology, 32 (3-4), 47-54.
https://www.kup.at/kup/pdf/15640.pdf
Need assistance with planning and executing your clinical study or investigation?
We are always interested in exchanging perspectives with innovators, sponsors, and clinical partners working at the intersection of technology and vascular health.
Our team guides you through all steps of your clinical study—from selecting the optimal study design to compliant implementation. This way, you can save time and costs without compromising on quality. Use clinical studies as a strategic tool to advance your product development effectively and establish a strong foundation for a successful market launch.
We are here to help and support you in developing an optimal clinical strategy for safe, effective, and market-ready products. Our expert team ensures smooth planning and execution of clinical studies that meet both, regulatory requirements and your project goals.
Explore our website to learn more about how we can support you as a medical device manufacturer. Feel free to contact us at studien@vascage.at.
